In COVID-19 clinical update #107, Daniel Griffin discusses Moderna vaccine results in children, hospitalization by ethnicity, BA.2 severity in children, placentitis and thrombohematoma during pregnancy, predictive value of symptoms for diagnosis, Evusheld activity against BA.1 and BA.2, Remdesivir resistance, Ivermectin with and without strongyloidiasis, inhaled ciclesonide, home telemonitoring, pulse oximetry for remote monitoring, effectiveness of anti-platelet therapy, and deaths in Zambia.
TWiV reviews the emergence of remdesivir-resistant SARS-CoV-2 during treatment of a persistently infected immunocompromised patient, and how altered TMPRSS2 utilization by the Omicron variant influences infectivity and fusion.
In COVID-19 clinical update #106, Daniel Griffin covers failure of ivermectin to improve hospitalization, increased hospitalization of children with Omicron, seroconversion of children versus adults, effectiveness of Pfizer mRNA vaccine in children, high vaccine effectiveness in Finland against Omicron, distinct long COVID clinical phenotypes, and estimating worldwide excess mortality.
TWiV discusses the virome of game animals in China, and the finding that binding of sarbecoviruses to ACE2 is an ancestral and evolvable trait.
In COVID-19 clinical update #105, Daniel Griffin discusses changes in brain structure after infection, dementia in patients with pneumonia, Paxlovid in children, mask effectiveness in schools, host factors and severe disease, post-acute symptoms, and the mission of CEPI.
In COVID-19 clinical update #104, Daniel Griffin reviews effectiveness of mRNA vaccines among children, number of children affected by disease, accuracy of rapid antigen tests, CDC guidance for prevention strategies, monoclonal antibody effectiveness, predicting progression to severe respiratory failure from pneumonia, risk of long COVID after two vaccine doses, and peripheral neuropathy in long COVID.
TWiV discusses whether or not Omicron should be designated a new serotype of SARS-CoV-2, and the finding that amino acid changes that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway.
In COVID-19 clinical update #103, Daniel Griffin covers immunocompromised people, hospitalization of children, vaccine usage update, Omicron and cross-reactive neutralizing antibodies, reinfection prevents disease in hamsters, repeated infections with endemic coronaviruses, global burden of antimicrobial resistance, ivermectin not protective in hamsters, and Omicron evades therapeutic monoclonals.
TWiV reviews epidemiological and experimental evidence that infection with Epstein-Barr virus leads to the production of antibodies against a viral protein that cross-react with a human protein, leading to multiple sclerosis.
In COVID-19 clinical update #102, Daniel Griffin reviews children and COVID, effectiveness of maternal vaccination, vaccines for immunocompromised, primary care physicians and vaccination rates, booster safety among adults, placentitis, azithromycin, oral Nirmatrelvir, Omicron antibody evasion, EUA for bebtelovimab, IL-1 blocking agents, thromboprophylaxis, effectiveness of vaccines against long COVID, and risks of mental health outcomes.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Brianne Barker, Ph.D.
Rich Condit, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.
Kathy Spindler, Ph.D.